Detectability and reproducibility of plasma levels of chemokines and soluble receptors

Results in Immunology

Volumn 3, Issue , 2013, Pages 79-84

  Agalliu, Ilir ^a   Xue, Xiaonan ^a   Cushman, Mary ^b   Cornell, Elaine ^c   Hsing, Ann W ^d,e   Kaplan, Robert C ^a   Anastos, Kathryn ^a   Rajpathak, Swapnil ^a,f   Ho, Gloria Y F ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biomarker; Chemokines; Limit of detection; Soluble receptors; Within subject variability

Indexed keywords

CHEMOKINE; CYTOKINE RECEPTOR; EOTAXIN 3; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 4 RECEPTOR; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1BETA; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; LIMIT OF DETECTION; MALE; MEASUREMENT REPEATABILITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REPRODUCIBILITY;

EID: 84882951380     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2013.07.001     Document Type: Article

References (39)

1. Balkwill F, Mantovani A Inflammation and cancer: Back to Virchow?. Lancet 2001, 357:539-545.
2. Coussens LM, Werb Z Inflammation and cancer. Nature 2002, 420:860-867.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nature Reviews Cancer 2007, 7:256-269.
4. Grivennikov SI, Greten FR, Karin M Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
5. Mantovani A, Sica A Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology 2010, 22:231-237.
6. de Visser KE, Coussens LM The inflammatory tumor microenvironment and its impact on cancer development. Contributions to Microbiology 2006, 13:118-137.
7. Gerber PA, Hippe A, Buhren BA, Muller A, Homey B Chemokines in tumor-associated angiogenesis. Biological Chemistry 2009, 390:1213-1223.
8. Ben-Baruch A Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Seminars in Cancer Biology 2006, 16:38-52.
9. de Visser KE, Eichten A, Coussens LM Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer 2006, 6:24-37.
10. Rosenkilde MM, Schwartz TW The chemokine system-a major regulator of angiogenesis in health and disease. APMIS 2004, 112:481-495.
11. Culig Z Cytokine disbalance in common human cancers. Biochimica et Biophysica Acta 2011, 1813:308-314.
12. Wang D, Dubois RN, Richmond A The role of chemokines in intestinal inflammation and cancer. Current Opinion in Pharmacology 2009, 9:688-696.
13. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer and Metastasis Reviews 2006, 25:357-371.
14. Scheller J, Ohnesorge N, Rose-John S Interleukin-6 trans-signalling in chronic inflammation and cancer. Scandinavian Journal of Immunology 2006, 63:321-329.
15. Yang F, Jin C, Jiang YJ, Li J, Di Y, et al. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Expert Review of Anticancer Therapy 2011, 11:541-549.
16. Lin WW, Karin M A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation 2007, 117:1175-1183.
17. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell JA, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009, 20:15-26.
18. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. Journal of the National Cancer Institute 2011, 103:1112-1122.
19. Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiology, Biomarkersand Prevention 2011, 20:971-977.
20. Ho GY, Xue XN, Burk RD, Kaplan RC, Cornell E, Cushman M Variability of serum levels of tumor necrosis factor-alpha, interleukin 6, and soluble interleukin 6 receptor over 2 years in young women. Cytokine 2005, 30:1-6.
21. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiology, Biomarkersand Prevention 2008, 17:3450-3456.
22. Linkov F, Gu Y, Arslan AA, Liu M, Shore RE, Velikokhatnaya L, et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. European Cytokine Network 2009, 20:21-26.
23. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunology 2009, 10:52.
24. Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009, 45:44-49.
25. Chaturvedi AK, Kemp TJ, Pfeiffer RM, Biancotto A, Williams M, Munuo S, et al. Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiology, Biomarkersand Prevention 2011, 20:1902-1911.
26. Hofmann JN, Yu K, Bagni RK, Lan Q, Rothman N, Purdue MP Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial. Cytokine 2011, 56:145-148.
27. Navarro SL, Brasky TM, Schwarz Y, Song X, Wang CY, Kristal AR, et al. Reliability of serum biomarkers of inflammation from repeated measures in healthy individuals. Cancer Epidemiology, Biomarkersand Prevention 2012, 21(7):1167-1170.
28. Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, et al. Temporal reliability of cytokines and growth factors in EDTA plasma. BMC Research Notes 2010, 3:30. 10.1186/1756-0500-3-302.
29. Ho GY, Melman A, Liu SM, Li M, Yu H, Negassa A, et al. Polymorphism of the insulin gene is associated with increased prostate cancer risk. British Journal of Cancer 2003, 88:263-269.
30. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998, 9:117-125.
31. Kaplan RC, Ho GY, Xue X, Rajpathak S, Cushman M, Rohan TE, et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiology, Biomarkersand Prevention 2007, 16:1291-1293.
32. Helsel D. Less than obvious-statistical treatment of data below the detection limit. Environmental Science and Technology 1990, 24:1766-1774.
33. Hornung R, Reed LD Estimation of average concentration in the presence of non-detectable values. Applied Occupational and Enviromental Hygiene 1990, 5:46-51.
34. Rosner B. Fundamentals of biostatistics 2011, 568-572. Brooks Cole, [chapter 12, Multisample inference].
35. Chiba K, Watanabe T, Ikeda M Variability of serum high density lipoprotein cholesterol concentration in healthy subjects in a three year term. Journal of Epidemiology and Community Health 1984, 38:195-197.
36. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiology, Biomarkersand Prevention 2006, 15:972-978.
37. Dugue B, Leppanen E Short-term variability in the concentration of serum interleukin-6 and its soluble receptor in subjectively healthy persons. Clinical Chemistry and Laboratory Medicine 1998, 36:323-325.
38. Sites CK, Toth MJ, Cushman M, L'Hommedieu GD, Tchernof A, Tracy RP, et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertility and Sterility 2002, 77:128-135.
39. McIlhenny C, George WD, Doughty JC A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers. British Journal of Cancer 2002, 86:1786-1789.